Vimarsana
Biggest News Aggregation in the World

Page 15 - Solid Tumor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumor Today - Breaking & Trending Today

Poseida taps former Novartis VP as president of gene therapy - Vimarsana News

Poseida taps former Novartis VP as president of gene therapy

Poseida Therapeutics has hired former Novartis Vice Presiden

St. Jude's Kids Get Support From Four-Legged Furry Friends - Vimarsana News

St. Jude's Kids Get Support From Four-Legged Furry Friends

The Paws at Play program at St. Jude Children's Research Hospital plays a very important part in helping families cope with their child's diagnosis. They are trained as service dogs that distract patients from their symptoms, illness, pain, and anxiety. They are there to motivate and support too with social interaction.

Source: wgna.com
AstraZeneca success torpedoes PCI's pivotal plan, crushing stock - Vimarsana News

AstraZeneca success torpedoes PCI's pivotal plan, crushing stock

The shock waves caused by the success of AstraZeneca’s TOPAZ-1 clinical trial have reached Norway. After reviewing the results, PCI Biotech has decided to scrap its own pivotal advanced biliary tract cancer trial in the belief it may struggle to complete the study and win approval. 

JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal - Vimarsana News

JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal

Moderna is doling out a little bit of its COVID-19 vaccine cash in a $45 million oncology research deal with Carisma Therapeutics to develop up to a dozen targets.

Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial - Vimarsana News

Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial

Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround.